Apwouve nan GLP1

exenatide (non mak Byetta ak Bydureon, manifaktire pa AstraZeneca), apwouve nan 2005/2012

liraglutide (Victoza pou dyabèt, Saxenda pou obezite, manifaktire pa Novo Nordisk), apwouve an 2010^[34]

albiglutide (Tanzeum, manifaktire pa GSK), apwouve nan 2014^[35]

dulaglutide (Trulicity, manifaktire pa Eli Lilly), apwouve nan 2014^[36]

lixisenatide (Lyxumia an Ewòp, Adlyxin nan Etazini, manifaktire pa Sanofi), apwouve nan 2016^[37]

semaglutide (Ozempic ak Rybelsus pou dyabèt, Wegovy pou obezite, manifaktire pa Novo Nordisk), apwouve an 2017^[38]

tirzepatide (double GLP-1 ak GIP agonist; Mounjaro pou dyabèt, Zepbound pou obezite, ki te fabrike pa Eli Lilly), apwouve an 2022^[39]